Notice of Q1 FY23 Results
![](https://tracker.live.rns-distribution.com/track.live-rns/4586673_6b796387bafb461f41df962c3713dcaf.png)
("Renalytix" or the "Company")
Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on
Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.
Webcast Registration link: https://edge.media-server.com/mmc/p/88vepbze
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the
For further information, please contact:
|
|||
|
Via Walbrook PR |
||
|
|
||
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
||
|
|
||
|
|
||
|
Tel: 020 7597 4000 |
||
|
|
||
|
|
||
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
||
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
||
CapComm Partners |
Tel: 415-389-6400 or investors@renalytix.com
|
||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the